tetano
Editor, Senior Moderator
Nat Commun
. 2024 Jul 11;15(1):5847.
doi: 10.1038/s41467-024-50052-2. SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023
Juan Manuel Carreño[SUP] #[/SUP][SUP] 1 2 [/SUP], Abram L Wagner[SUP] #[/SUP][SUP] 3 [/SUP], Brian Monahan[SUP] 1 2 [/SUP], Gagandeep Singh[SUP] 1 2 [/SUP], Daniel Floda[SUP] 4 [/SUP], Ana S Gonzalez-Reiche[SUP] 4 [/SUP], Johnstone Tcheou[SUP] 1 2 [/SUP], Ariel Raskin[SUP] 1 2 [/SUP], Dominika Bielak[SUP] 1 2 [/SUP], Sara Morris[SUP] 1 2 [/SUP], Miriam Fried[SUP] 1 2 [/SUP], Temima Yellin[SUP] 1 2 [/SUP], Leeba Sullivan[SUP] 1 2 [/SUP]; PARIS study group; Emilia Mia Sordillo[SUP] 5 [/SUP], Aubree Gordon[SUP] 6 [/SUP], Harm van Bakel[SUP] 7 8 9 10 [/SUP], Viviana Simon[SUP] 11 12 13 14 15 [/SUP], Florian Krammer[SUP] 16 17 18 19 [/SUP]
Collaborators, Affiliations
Sero-monitoring provides context to the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and changes in population immunity following vaccine introduction. Here, we describe results of a cross-sectional hospital-based study of anti-spike seroprevalence in New York City (NYC) from February 2020 to July 2022, and a follow-up period from August 2023 to October 2023. Samples from 55,092 individuals, spanning five epidemiological waves were analyzed. Prevalence ratios (PR) were obtained using Poisson regression. Anti-spike antibody levels increased gradually over the first two waves, with a sharp increase during the 3rd wave coinciding with SARS-CoV-2 vaccination in NYC resulting in seroprevalence levels >90% by July 2022. Our data provide insights into the dynamic changes in immunity occurring in a large and diverse metropolitan community faced with a new viral pathogen and reflects the patterns of antibody responses as the pandemic transitions into an endemic stage.
. 2024 Jul 11;15(1):5847.
doi: 10.1038/s41467-024-50052-2. SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023
Juan Manuel Carreño[SUP] #[/SUP][SUP] 1 2 [/SUP], Abram L Wagner[SUP] #[/SUP][SUP] 3 [/SUP], Brian Monahan[SUP] 1 2 [/SUP], Gagandeep Singh[SUP] 1 2 [/SUP], Daniel Floda[SUP] 4 [/SUP], Ana S Gonzalez-Reiche[SUP] 4 [/SUP], Johnstone Tcheou[SUP] 1 2 [/SUP], Ariel Raskin[SUP] 1 2 [/SUP], Dominika Bielak[SUP] 1 2 [/SUP], Sara Morris[SUP] 1 2 [/SUP], Miriam Fried[SUP] 1 2 [/SUP], Temima Yellin[SUP] 1 2 [/SUP], Leeba Sullivan[SUP] 1 2 [/SUP]; PARIS study group; Emilia Mia Sordillo[SUP] 5 [/SUP], Aubree Gordon[SUP] 6 [/SUP], Harm van Bakel[SUP] 7 8 9 10 [/SUP], Viviana Simon[SUP] 11 12 13 14 15 [/SUP], Florian Krammer[SUP] 16 17 18 19 [/SUP]
Collaborators, Affiliations
- PMID: 38992013
- DOI: 10.1038/s41467-024-50052-2
Sero-monitoring provides context to the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and changes in population immunity following vaccine introduction. Here, we describe results of a cross-sectional hospital-based study of anti-spike seroprevalence in New York City (NYC) from February 2020 to July 2022, and a follow-up period from August 2023 to October 2023. Samples from 55,092 individuals, spanning five epidemiological waves were analyzed. Prevalence ratios (PR) were obtained using Poisson regression. Anti-spike antibody levels increased gradually over the first two waves, with a sharp increase during the 3rd wave coinciding with SARS-CoV-2 vaccination in NYC resulting in seroprevalence levels >90% by July 2022. Our data provide insights into the dynamic changes in immunity occurring in a large and diverse metropolitan community faced with a new viral pathogen and reflects the patterns of antibody responses as the pandemic transitions into an endemic stage.